Abiomed, Inc announced the availability of webcast of an Impella 2.5 procedure performed on an 85-year-old male with multi-vessel disease at Mount Sinai Medical Center.
The webcast presents high-risk percutaneous coronary intervention (PCI) performed by by Samir Sharma, M.D., director of the catheterization lab (cath lab) and interventions, and Annapoorna Kini, M.D., associate professor of the cath lab at Mount Sinai Medical Center. The procedure was performed successfully with Impella 2.5 support.
An 85-year-old male patient with multi-vessel disease had reported 20% left ventricular ejection fraction (LVEF), in the sense that his heart’s left ventricle was only pumping 20 percent of its volume with each beat which should be generally ranging from 60 – 65 percent in normal patients. Impella 2.5 provided left ventricular support and hemodynamic stability. “(Impella) gives operators the confidence to achieve good results without worrying about hemodynamic compromise,” states Dr. Sharma during the live webcast.
“Mount Sinai Medical Center is renowned for its high volumes and exceptional outcomes,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “We are honored that Impella is considered one of the primary options for hemodynamic support and complete revascularization in high-risk PCI cases.”